Transformative pain therapeutics
Changing the course of pain for patients who need it most
Who we are
Adynxx, located in San Francisco, is a clinical-stage biotechnology company developing a transformative technology platform addressing pain at its molecular roots. Adynxx’s unique approach is to transform pain management by approaching pain as a disease rather than a symptom.
Provide safe, non-opioid, long-term pain reduction with a single administration
Developing transformative, first-in-class therapies to address significant unmet medical needs
A proprietary platform of non-opioid, disease-modifying oligonucleotide therapeutics
Tackling high unmet need
Focusing on patients who have the greatest need for innovative pain treatments
News & Publications
Oct 12, 2018
LANGHORNE, Pa. & SAN FRANCISCO, October 12, 2018 -- Alliqua BioMedical, Inc. (Nasdaq:ALQA) and Adynxx, Inc., a privately held biopharmaceutical company, today announced that they have entered into a definitive merger agreement under which the stockholders of Adynxx would become the majority owners of Alliqua’s outstanding common stock on a fully-diluted basis. The proposed merger will create a public clinical-stage pharmaceutical company focused on developing a platform of first-in-class, disease-modifying, non-opioid therapies for the treatment of pain.
Meet our team
Experienced management team with a proven track record of success dedicated to improving the life of patients